Sonoma Pharmaceuticals, Inc. (NasdaqCM:SNOA) announced that it has commenced a process to explore and evaluate strategic alternatives for its U.S. Dermatology Division and has engaged Maxim Group LLC as its financial advisor to assist in this process. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated. Amy Trombly, Chief Executive Officer of Sonoma said, “We’ve developed a portfolio of quality dermatology products that are highly valued by our customers. We look forward to working with Maxim to develop a strategy to maximize the value of this portfolio for our shareholders”.